Findings from this study demonstrating the high prevalence of asthma/AHR in endurance versus nonendurance sports are consistent with those of previously published studies showing that endurance training itself is an etiologic factor in the development of asthma.6, 30, 41 This finding raises the question of whether prolonged endurance training leading to the development of asthma has a negative effect on performance. A study evaluating athlete performance with a TUE for IBAs in the 2000 Sydney Olympic Games showed that the 5.7% of athletes with a valid TUE for IBAs were responsible for winning 7.2% of the medals. Likewise, in a study of TUEs in the 2004 Athens Olympic Games, McKenzie and Fitch42 demonstrated that 4.2% of all athletes with a TUE for IBAs won 5.4% of all individual medals. Fitch29 looked specifically at swimming results in the 2008 Beijing Olympic Games and reported that the 19.3% of swimmers with a TUE for IBAs won 32.9% of all aquatic medals. Clearly, asthma/AHR in the elite swimmer does not have a negative effect on performance; indeed, this study demonstrates that athletes with TUEs for asthma/AHR perform better.
There are many possible theories for why athletes with asthma perform better than athletes without asthma. Is this phenomenon due to a longer training period, resulting in the development of asthma along with more efficient swimming skills? Does this represent a genetic predisposition for asthma and superior aquatic performance? This also raises the question of whether the use of IBA or inhaled corticosteroid therapy is performance enhancing. Kuipers et al,43 Kinderman,44 and Pluim et al45 have shown that neither substance, when used in therapeutic doses, is performance enhancing. Could there be a perceived placebo effect of performance enhancement with IBAs? Couto et al46 demonstrated that the prevalence of asthma/AHR declaration decreased by half when the mandatory objective measures required by WADA were implemented, suggesting that before the WADA TUE requirements, athletes were using IBAs without an accurate diagnosis of asthma/AHR, potentially for the falsely perceived performance benefit of the drugs.